{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:06:56Z","timestamp":1786975616636,"version":"build-2736575974"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2018,6,1]]},"DOI":"10.1001\/jamadermatol.2018.0793","type":"journal-article","created":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T18:30:57Z","timestamp":1526581857000},"page":"676","source":"Crossref","is-referenced-by-count":114,"title":["Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions"],"prefix":"10.1001","volume":"154","author":[{"given":"Peter","family":"Foley","sequence":"first","affiliation":[{"name":"Department of Medicine, The University of Melbourne, St Vincent\u2019s Hospital, Melbourne, Victoria, Australia"},{"name":"Skin & Cancer Foundation Inc, Carlton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Gordon","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E. M.","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Salford Royal Hospital, University of Manchester, Manchester Academic Health Science Centre, Manchester, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Wasfi","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Spring House, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Randazzo","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Spring House, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Song","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Spring House, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Li","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Spring House, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaung-Kaung","family":"Shen","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Spring House, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[{"name":"Oregon Medical Research Center, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"doi180015r1","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/jdv.2007.21.issue-9","article-title":"Scalp psoriasis: a review of current topical treatment options.","volume":"21","author":"Papp","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"doi180015r2","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.jaad.2008.11.890","article-title":"Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation.","volume":"60","author":"Chan","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi180015r3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0733-8635(18)30876-3","article-title":"Psoriasis of the nail.","volume":"3","author":"Scher","year":"1985","journal-title":"Dermatol Clin"},{"issue":"3","key":"doi180015r4","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1080\/00015550260132488","article-title":"Palmoplantar lesions in psoriasis: a study of 3065 patients.","volume":"82","author":"Kumar","year":"2002","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"doi180015r5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1001\/archderm.138.6.803","article-title":"Scalpdex: a quality-of-life instrument for scalp dermatitis.","volume":"138","author":"Chen","year":"2002","journal-title":"Arch Dermatol"},{"issue":"2","key":"doi180015r6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1067\/S0190-9622(03)01479-8","article-title":"Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice.","volume":"49","author":"Pettey","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"doi180015r7","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1111\/jdv.2014.28.issue-12","article-title":"Nail psoriasis, the unknown burden of disease.","volume":"28","author":"Klaassen","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"doi180015r8","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.3899\/jrheum.140881","article-title":"Treatments for nail psoriasis: a systematic review by the GRAPPA Nail Psoriasis Work Group.","volume":"41","author":"Armstrong","year":"2014","journal-title":"J Rheumatol"},{"issue":"7","key":"doi180015r9","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1111\/jdv.12198","article-title":"Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and\/or feet: post hoc analysis of REACH.","volume":"28","author":"Poulin","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"doi180015r10","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1080\/09546634.2016.1249820","article-title":"Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3).","volume":"28","author":"Reich","year":"2017","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"doi180015r11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti\u2013interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi180015r12","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti\u2013interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi180015r13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/jdv.12553","article-title":"Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study.","volume":"29","author":"Tha\u00e7i","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi180015r14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaad.2016.07.058","article-title":"Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial.","volume":"76","author":"Gottlieb","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi180015r15","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/bjd.2014.170.issue-2","article-title":"Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1.","volume":"170","author":"Rich","year":"2014","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi180015r17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1067\/S0190-9622(03)00910-1","article-title":"Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis.","volume":"49","author":"Rich","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi180015r18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/ced.1994.19.issue-3","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use.","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"doi180015r19","first-page":"174","article-title":"Nail psoriasis.","volume":"50","author":"Farber","year":"1992","journal-title":"Cutis"},{"issue":"5","key":"doi180015r20","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.clindermatol.2007.10.026","article-title":"Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas.","volume":"26","author":"Wozel","year":"2008","journal-title":"Clin Dermatol"},{"issue":"7","key":"doi180015r21","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/jdv.2009.23.issue-7","article-title":"A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients.","volume":"23","author":"Adisen","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"doi180015r22","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1111\/j.1468-3083.2011.03984.x","article-title":"Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study.","volume":"25","author":"Bissonnette","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi180015r23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0733-8635(05)70145-5","article-title":"Developments in the treatment of nail psoriasis, melanonychia striata, and onychomycosis: a review of the literature.","volume":"18","author":"Van Laborde","year":"2000","journal-title":"Dermatol Clin"},{"issue":"3","key":"doi180015r24","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/jdv.2017.31.issue-3","article-title":"Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.","volume":"31","author":"van de Kerkhof","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"doi180015r25","first-page":"272","article-title":"Improvement of nail and scalp psoriasis using apremilast in patients with chronic psoriasis: phase 2b and 3, 52-week randomized, placebo-controlled trial results.","volume":"15","author":"Nguyen","year":"2016","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"doi180015r26","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jaad.2007.07.042","article-title":"Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year.","volume":"58","author":"Rich","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi180015r27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jaad.2015.09.001","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).","volume":"74","author":"Rich","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi180015r28","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1111\/bjd.2013.168.issue-5","article-title":"A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis.","volume":"168","author":"Ortonne","year":"2013","journal-title":"Br J Dermatol"},{"issue":"12","key":"doi180015r29","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1111\/jdv.2014.28.issue-12","article-title":"Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial.","volume":"28","author":"Paul","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"doi180015r16","unstructured":"International Conference on Harmonisation Guideline for Good Clinical Practice. Efficacy single. http:\/\/www.ich.org\/products\/guidelines\/efficacy\/efficacy-single\/article\/integrated-addendum-good-clinical-practice.html. Accessed April 2, 2018."}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2681556","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T01:22:16Z","timestamp":1571361736000},"score":1,"resource":{"primary":{"URL":"http:\/\/archderm.jamanetwork.com\/article.aspx?doi=10.1001\/jamadermatol.2018.0793"}},"subtitle":["A Secondary Analysis of 2 Randomized Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2018.0793","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6,1]]}}}